• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

CoreRx adds particle engineering capabilities with Bend Bioscience deal

According to early stage CDMO Bend Bioscience, the company is now part of Florida-based CDMO CoreRx thanks to an equity investment by NovaQuest Private Equity, which acquired CoreRx in 2021. Bend Bioscience, which launched in 2021, will offer particle engineering and manufacturing services for a range of dosage forms, including dry powders for inhalation. Bend Bioscience’s founders and most of its personnel previously worked for spray-drying specialist Bend Research and then for Lonza following Capsugel’s acquisition of Bend Research in 2013 and Lonza’s acquisition of Capsugel in 2017.

The deal includes funding for new facilities in Bend, Oregon, including a ~20,000 sq ft laboratory and processing space, plus offices designed for a staff of 50 employees, and Bend says that it is actively recruiting for a number of positions. The lab may be ready for operations by the end of 2022, the company says; the remainder of the analytical and manufacturing capabilities are expected to be ready by the middle of 2023. 

CoreRx and Bend Bioscience CEO Ajay Damani said, “This is an exciting development with Bend Bioscience adding a new dimension of technology and innovation capabilities to CoreRx’s existing foundation of product development and manufacturing solutions.”

CoreRx Chief Strategy Officer Dan Dobry, a co-founder of Bend Bioscience, added, “We feel Bend Bioscience will fill an unmet need, offering problem solving, formulation, and manufacturing for valuable but challenging therapies and collaborating to develop new technologies for the rapidly evolving problem statements in the in pharmaceutical industry.”

Read the Bend Bioscience press release.

Share

published on October 14, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews